68419-38-5

Usage

Uses

Used in Pharmaceutical Industry:
(R)-(+)-PIPERIDINE-2-ETHANOL is used as a key intermediate in the synthesis of a novel class of pyrazolopyrimidines. These compounds serve as inhibitors of protein and checkpoint kinases, which are important targets for the development of new therapeutics.
Used in Antiviral Applications:
(R)-(+)-PIPERIDINE-2-ETHANOL is used as a therapeutic agent for the treatment and prophylaxis of Hepatitis C Virus (HCV) infection. Its antiviral properties make it a valuable compound in the development of new treatments for this disease.
Used in Oncology:
(R)-(+)-PIPERIDINE-2-ETHANOL is also useful in the treatment of various types of cancer. Its potential applications in oncology are being explored, as it may contribute to the development of new cancer therapies by targeting specific cellular pathways or enhancing the efficacy of existing treatments.

Upstream product

• 1484-84-0 2(RS)-(2-hydroxyethyl)piperidine 
• 327158-11-2 1-[(R)-1-(2-Hydroxy-phenyl)-ethyl]-piperidine-2,6-dione 
• 327158-12-3 (9aS,10R)-10-Methyl-1,2,3,9a-tetrahydro-10H-9-oxa-4a-aza-anthracen-4-one 
• 108-55-4 glutaric anhydride, 
• 327158-15-6 {(R)-1-[(R)-1-(2-Methoxy-phenyl)-ethyl]-6-oxo-piperidin-2-yl}-acetaldehyde 
• 327158-13-4 (R)-6-Allyl-1-[(R)-1-(2-hydroxy-phenyl)-ethyl]-piperidin-2-one 

Downstream Products

• 121524-18-3 (2R)-1-[3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-2-(2-hydroxyethyl)piperidine 
• 19832-04-3 (R)-2-(piperidin-2'-yl)ethanoic acid 
• 351410-32-7 (R)-2-(1-(tert-butoxycarbonyl)piperidin-2-yl) acetic acid 
• 813433-73-7 (R)-2-methoxycarbonylmethylpiperidine-1-carboxylic acid tert-butyl ester 
• 250249-85-5 (R)-2-(2-hydroxy-ethyl)-piperidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Expanded substrate scope and catalyst optimization for the catalytic kinetic resolution of N-heterocycles

The scope, reactivity, and selectivity of the chiral hydroxamic acid-catalyzed kinetic resolution of chiral amines are improved by a new catalyst structure and a more environmentally friendly reaction protocol. In addition to increasing selectivity across all substrates, these conditions make possible the resolution of N-heterocycles containing lactams or other basic functional groups that can inhibit the catalyst.

Process and intermediates for the synthesis of (3-alkyl-5-piperidin-1-yl-3,3a-dihydro-pyrazolo[1,5-a]pyrimidin-7-yl)-amino derivatives and intermediates

This application discloses a novel process to synthesize (3-alkyl-5-piperidin-1-yl-3,3a-dihydro-pyrazolo[1,5-a]pyrimidin-7-yl)-amino derivatives, and intermediates useful in the synthesis thereof. The subject (3-alkyl-5-piperidin-1-yl-3,3a-dihydro-pyrazolo[1,5-a]pyrimidin-7-yl)-amino derivatives are useful as cyclin-dependent kinase inhibitor compounds (CDK inhibitors) in pharmaceutical preparations.

Total synthesis of (-)-senepodine G and (-)-cermizine C

(Chemical Equation Presented) An efficient, stereospecific synthesis of the alkaloids senepodine G (2) and cermizine C (1) has been completed using the BF3·Et2O-promoted stereospecific addition of Me2CuLi to α,β-unsaturated lactam 6 to provide lactam 3, the addition of MeMgBr followed by HCl to convert 3 to senepodine G (2) (six steps, 40% overall yield), and the stereospecific NaBH4 reduction of 2 to give cermizine C (1) (seven steps, 40% overall yield).

Pyrazolotriazines as kinase inhibitors

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]triazine compounds as inhibitors of kinases such as, for example, cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing

Total synthesis of (-)-stellettamide B and determination of its absolute stereochemistry.

[figure: see text] The first total synthesis of (-)-stellettamide B has been achieved by a sequence based on amide coupling of the chiral 1-(aminomethyl)-indolizidine fragment, prepared by TiCl4-mediated asymmetric allylation of the tricyclic N-acyl-N,O-a

Process development of a novel non-xanthine adenosine A1 receptor antagonist

(+)-(R)-1-[(E)-3-(2-phenylpyrazolo[l,5-a]pyridin-3-yl)acryloyl]-2- piperidine ethanol (FK453) is a novel, potent adenosine AI receptor antagonist for the regulation of renal function. The development of a reliable process suitable for large scale manufacture is described. A Horner-Emmons reaction and a 1,3-dipolar cycloaddition were successfully scaled up to afford ethyl (E)-3-(2-phenylpyrazolo[l,5-a]pyridin-3-yl)acryloylate, with excellent regioselectivity and stereoselectivity. Process improvements and optimization of each step permitted elimination of column chromatography, resulting in a straightforward, practical synthesis of FK453.